OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Jennifer Pritzker Sells 4,000 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Jennifer Pritzker sold 4,000 shares of the stock in a transaction on Monday, August 24th. The shares were sold at an average price of $25.75, for a total value of $103,000.00. Following the sale, the insider directly owned 6,897,764 shares in the company, valued at approximately $177,617,423. The trade was a 0.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

OrthoPediatrics Price Performance

Shares of NASDAQ:KIDS opened at $24.03 on Thursday. OrthoPediatrics Corp. has a 52 week low of $14.42 and a 52 week high of $26.74. The business has a fifty day simple moving average of $21.23 and a 200-day simple moving average of $18.58. The company has a market cap of $627.42 million, a P/E ratio of -14.30 and a beta of 0.98. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The business had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. Equities research analysts forecast that OrthoPediatrics Corp. will post -1.14 EPS for the current year.

Wall Street Analyst Weigh In

KIDS has been the topic of several research analyst reports. Truist Financial set a $22.00 price objective on OrthoPediatrics in a research note on Wednesday, August 5th. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. BTIG Research upped their price target on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Piper Sandler reiterated an “overweight” rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Finally, Needham & Company LLC upped their price objective on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $26.44.

OrthoPediatrics News Roundup

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics completed the full U.S. commercial launch of its 3P™ Pediatric Plating Platform® Hip System after more than 350 successful implantations during a limited release. The company said the system addresses pediatric hip trauma and deformities, improves fixation and surgical workflow, and is the first of several planned systems in a broader plating portfolio. The launch provides a potential long-term revenue and market-share opportunity, although the company did not provide specific financial guidance. OrthoPediatrics Announces Full Commercial Launch of 3P Pediatric Plating Platform Hip System
• Neutral Sentiment: Reported short interest was listed as zero shares with a zero-day short-interest ratio. However, the filing data also showed an invalid “NaN” change, making the statistic unreliable and providing little usable insight into potential short-selling pressure.
• Negative Sentiment: Director David R. Pelizzon and major shareholder entities associated with Squadron Capital and Jennifer N. Pritzker reported sales totaling 38,300 shares for approximately $943,302 across August 24–26, at prices ranging from $24.28 to $25.75. The transactions reduced the reported position by only about 0.56%, leaving ownership of roughly 6.86 million shares, so the sales appear relatively small compared with the remaining stake. Nevertheless, repeated insider selling can weigh on sentiment, particularly with KIDS trading near its 52-week high. SEC insider transaction filing

Hedge Funds Weigh In On OrthoPediatrics

Hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. grew its holdings in shares of OrthoPediatrics by 433.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after purchasing an additional 1,139 shares during the last quarter. Legal & General Group Plc acquired a new position in shares of OrthoPediatrics during the second quarter valued at $34,000. Northwestern Mutual Wealth Management Co. lifted its position in OrthoPediatrics by 5,226.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after purchasing an additional 2,561 shares during the period. Caption Management LLC acquired a new stake in OrthoPediatrics during the 3rd quarter worth $54,000. Finally, BNP Paribas Financial Markets grew its stake in shares of OrthoPediatrics by 60.2% during the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after purchasing an additional 1,235 shares during the period. 69.05% of the stock is owned by institutional investors and hedge funds.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.